Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide In silico docking and ADMET-based screening were applied to an in-house library of 52 virtual hybrids of 1,4-naphthoquinone substituted with natural moieties. Promising multidisease targeting hybrids with suitable druggability were synthesized and evaluated in vitro for their antibacterial, antifungal, and anticancer activities. The hybrid of 1,4-naphthoquinone with menthol ( 9 ), thymol ( 10 ), and uracil ( 17 ) exhibited a promising minimum inhibitory effect (MIC = 4–12 μg/mL) against the Gram-positive bacteria Bacillus cereus and B. subtilis, as well as the Gram-negative bacteria Serratia marcescens and Escherichia coli, along with antifungal activity against the strains Alternaria alternata and Aspergillus niger . The derivative 10 exhibited the highest anticancer activity (IC 50 = 4.59 μg/mL), while the rest showed IC 50 values in the 12.28- 62.98 μg/mL range against the human breast carcinoma cell line MCF-7. The 1,4-naphthoquinone-isoniazid hybrid ( 16 ) showed IC 50 values of 35.0, 3.0, and 0.3 μg/mL, respectively, against A549, MDA-MB-231, and SK-BR-3 cancer cell lines, while derivatives 9, 10, and 17 showed IC 50 in the range of 4–60 μg/mL. Meanwhile, the derivatives did not show toxicity to normal HEK-293 cells. The interaction of derivatives 10 and 16 with 4,5-diaryl isoxazole Hsp90 chaperone (PDB: 2VCJ ) was further verified through 100 ns molecular dynamics simulation studies. The findings support the possible use of 1,4-naphthoquinone hybrid scaffolds for addressing cancer and concurrent microbial infections.
No takes yet. Share an insight, caveat, or question.
Srivastava et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: